🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 163 of 857 · Phase 3 first, then by program name

  1. SB11 (Proposed ranibizumab biosimilar)

    Samsung Bioepis NL B.V.

    Age-Related Macular Degeneration

    phase 3 small molecule completed

    1 trial

  2. SBRT

    United Therapeutics Europe Ltd

    Prostate Cancer

    phase 3 other active

    3 trials

  3. SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety)

    Takeda

    Primary Immunodeficiency Diseases (PID)

    phase 3 mab completed

    1 trial

  4. SCENESSE 16 mg implant

    Clinuvel Europe Limited

    Vitiligo

    phase 3 small molecule active

    1 trial

  5. SD-809

    Teva Pharma GmbH

    Chorea Associated With Huntington Disease

    phase 3 small molecule completed

    1 trial

  6. SD-809

    Teva Pharma GmbH

    Tardive Dyskinesia

    phase 3 small molecule completed

    3 trials

  7. SD-809

    Teva Pharma GmbH

    Chorea

    phase 3 small molecule completed

    1 trial

  8. SDF solution

    The University of Hong Kong

    Dental Caries

    phase 3 other completed

    1 trial

  9. SECUKINUMAB

    Novartis Pharmaceuticals

    Polymyalgia Rheumatica

    phase 3 small molecule active

    1 trial

  10. SEG101

    Novartis Pharmaceuticals

    Sickle cell disease

    phase 3 small molecule active

    1 trial

  11. SELINEXOR, Selinexor placebo for 20 mg tablets is formulated for oral administration. selinexor placebo tablets are film coated bi-convex round tablets

    Karyopharm Therapeutics Inc

    endometrial cancer

    phase 3 small molecule active

    1 trial

  12. SELPERCATINIB, CARBOPLATIN , SELPERCATINIB, PEMBROLIZUMAB, CISPLATIN , PEMETREXED

    Eli Lilly Co.

    Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  13. SELUMETINIB, SELUMETINIB, Placebo to match Selumetinib capsules, 10 and 25 mg.

    AstraZeneca AB

    Neurofibromatosis Type 1 (NF1) with Symptomatic, Inoperable Plexiform Neurofibromas (PN).

    phase 3 small molecule active

    1 trial

  14. SER-109

    Seres Therapeutics

    Clostridium Difficile Infection

    phase 3 mab completed

    1 trial

  15. SER-109

    Seres Therapeutics

    Clostridioides Difficile Infection

    phase 3 mab completed

    1 trial

  16. SERTRALINE , LITHIUM , ESCITALOPRAM , QUETIAPINE, VENLAFAXINE , VALPROIC ACID , BUPROPION

    Disc Medicine

    Bipolar depression

    phase 3 small molecule active

    1 trial

  17. SEVOFLURANE, DEXMEDETOMIDINE HYDROCHLORIDE

    The George Institute

    Children under the age of 2 years having surgery lasting at least 2 hours

    phase 3 small molecule active

    1 trial

  18. SGM-101

    BRIGHT MINDS BIOSCIENCES INC.

    Rectal Cancer

    phase 3 small molecule active

    1 trial

  19. SGT-003

    Solid Biosciences

    Duchenne Muscular Dystrophy

    phase 3 gene therapy active

    2 trials

  20. SHP465

    Takeda

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    4 trials

  21. SHP465 12.5mg capsules (one capsule daily)

    Takeda

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    1 trial

  22. SHP615

    Takeda

    Nervous System Diseases

    phase 3 small molecule completed

    2 trials

  23. SHP615

    Shire

    Nervous System Diseases

    phase 3 small molecule completed

    1 trial

  24. SHP640

    Takeda

    Adenoviral Conjunctivitis

    phase 3 small molecule terminated

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources